Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
Sponsor: OBEcure Ltd.
Terminated
Interim Analysis result indicated the study will not show a significant benefit of the study medication on the primary endpoint.
Other terminated trials from OBEcure Ltd.
More terminations from OBEcure Ltd.
Listed as NCT00428168, this PHASE2 trial focuses on Weight Gain and remains terminated or withdrawn. Sponsored by OBEcure Ltd., it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OBEcure Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .